The will of Giorgio Armani obliges his fashion group to sell a 15% stake within 18 months of his death, putting L'Oréal, LVMH and EssilorLuxottica on a transactional clock that runs to roughly March 2027.

The designer, who died in September 2025 at 91, named the three groups as preferred buyers in his succession plan, according to people familiar with the document. Armani Group chief executive Giuseppe Marsocci confirmed the structure on 27 September on the sidelines of the brand's Milan fashion show, telling reporters the company intends to honour the timetable.

Who sits in the bidder field?

L'Oréal is the group's longest-standing beauty partner. The French company licensed fragrance, make-up and skin care under the Armani name in 1988 and renewed the agreement in 2018, extending the contract to 2050. That license is the central commercial asset in play, since any change of control at Armani Group typically requires a review of licensing economics, royalty rates and territorial scope.

LVMH brings a luxury conglomerate with selective beauty exposure through Dior, Givenchy and Fresh. EssilorLuxottica, the eyewear company, already produces and distributes Armani Eyewear worldwide. Both groups carry procurement and retail logic that overlaps with, but does not duplicate, L'Oréal's beauty franchise.

What did management signal in Milan?

Marsocci left the door open to splitting the 15% across more than one buyer. "It is not written in stone that it has to be one investor," he said, according to Reuters, while stressing that no decision has been made. He framed completion as contingent on reaching an agreement on "price and details".

The Financial Times reported that Armani Group is poised to hold meetings with all three prospective buyers in the coming weeks, an unusually short runway given the 18-month deadline and the size of the cosmetics and skin care business inside the perimeter.

How is L'Oréal positioning the bid?

L'Oréal's chief financial officer Christophe Babule addressed the question publicly in December 2025 at the group's Capital Markets Day, calling the heirs' approach a mark of trust.

"We are quite honoured by the consideration of the heirs of the family towards their willingness to see L'Oréal investing in their company," Babule said during a fireside chat with analysts. He added: "I cannot disclose more today, but this is the kind of thing you have to look at if you are a leader like L'Oréal in luxury beauty."

The comments stop short of a price disclosure or a financing structure, but signal that L'Oréal's executive committee has escalated the file from monitoring to active review.

What changes for beauty procurement and brand work?

For formulators, packaging teams and account leads working on the Armani line, the most immediate variable is not the stake itself but the license architecture wrapped around it. Three operational threads will move in parallel over the next two quarters:

• Royalty schedules and minimum-guarantee terms under the 1988 contract, extended in 2018 to a 2050 horizon.
• Governance rights at the Armani brand committee, where L'Oréal currently co-develops product roadmaps and approves packaging artwork.
• Distribution control in mainland China, the United States and the Gulf, where Armani fragrance and make-up over-index.

A single-buyer scenario would consolidate those decisions under one strategic owner. A split-stake outcome would require parallel coordination across luxury, beauty and eyewear boards, raising the compliance workload for the brand team while leaving the underlying license intact.

What to watch next

Armani Group has not commented on the meeting calendar reported by the FT. Industry observers will look for a non-binding offer letter from at least one of the three parties before the end of the first quarter, and for L'Oréal to confirm whether it will seek exclusive beauty terms inside any consortium structure. The next hard data point is the 15-month mark, when the heirs' legal advisers are expected to publish a status report on the dispositive process.